Effects of Atenolol or Losartan on Fibrinolysis and von Willebrand Factor in Hypertensive Patients With Left Ventricular Hypertrophy

Abstract

Objectives: To compare the effects of the β-blocker atenolol with the angiotensin receptor blocker (ARB) losartan on plasma tissue-type plasminogen activator (tPA) activity and mass concentration, plasminogen activator inhibitor-1 (PAI-1) activity, tPA/PAI-1 complex, and von Willebrand factor (VWF). Design: A prespecified, explorative substudy in 22 patients with hypertension and left ventricular hypertrophy (LVH) performed within randomized multicenter, double-blind prospective study. Results: After a median of 36 weeks of treatment, there were significant differences between the treatment groups, atenolol versus losartan, in plasma median levels of tPA mass (11.9 vs 7.3 ng/mL, P = .019), PAI-1 activity (20.7 vs 4.8 IU/mL, P = .030), and tPA/PAI-1 complex (7.1 vs 2.5 ng/mL, P = .015). In patients treated with atenolol, median levels of tPA mass (8.9-11.9 ng/mL, P = .021) and VWF (113.5%-134.3%, P = .021) increased significantly, indicating a change toward a more prothrombotic state. No significant changes occurred in the losartan group. Conclusion: Losartan treatment was associated with preserved fibrinolytic balance compared to a more prothrombotic fibrinolytic and hemostatic state in the atenolol group. These findings suggest different fibrinolytic and hemostatic responses to treatment in hypertensive patients with LVH.

Keywords

fibrinolysis von Willebrand factor hypertension left ventricular hypertrophy atenolol losartan

References

Eliasson M. , Jansson JH , Nilsson P. , Asplund K. Increased levels of tissue plasminogen activator antigen in essential hypertension . A population-based study in Sweden. J Hypertens. 1997;15(4):349-356.

Winther K. , Gleerup G. , Hedner T. Enhanced risk of thromboembolic disease in hypertension from platelet hyperfunction and decreased fibrinolytic activity: has antihypertensive therapy any influence ? J Cardiovasc Pharmacol. 1992;19(suppl 3):S21-S24.

Alderman MH , Ooi WL , Cohen H. , Madhavan S. , Sealey JE , Laragh JH Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens. 1997;10(1):1-8.

Boman KO , Jansson JH , Nyhlen KA , Nilsson TK Improved fibrinolysis after one year of treatment with enalapril in men and women with uncomplicated myocardial infarction. Thromb Haemost . 2002;87(2):311-316.

Ridker PM , Gaboury CL , Conlin PR , Seely EW , Williams GH , Vaughan DE Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation. 1993 ;87(6):1969-1973.

Sporn LA , Chavin SI , Marder VJ , Wagner DD Biosynthesis of van Willebrand protein by human megakaryocytes. J Clin Invest. 1985;76(3):1102-1106.

Nilsson TK , Boman K. , Bjerle P. , Hallmans G. , Hellsten G. von Willebrand factor and fibrinolytic variables are differently affected in the insulin resistance syndrome. J Intern Med. 1994;235(5):419-423.

Jansson JH , Nilsson TK , Johnson O. von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction. Heart. 1998 ;80(4):334-337.

Jansson JH , Johansson B. , Boman K. , Nilsson TK Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol. Eur J Clin Pharmacol . 1991;40(4):321-326.

10.

Dahlof B. , Zanchetti A. , Diez J. , et al., for the REGAAL Study Investigators. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy . J Hypertens. 2002;20(9):1855-1864.

11.

Bergsdorf N. , Nilsson T. , Wallén P. An enzyme linked immunosorbent assay for determination of tissue plasminogen activator applied to patients with thromboembolic disease . Thromb Haemost. 1983;50(3):740-744.

12.

Cejka J. Enzyme immunoassay for factor VIII-related antigen. Clin Chem . 1982;28(6):1356-1358.

13.

Zizek B. , Poredos P. Increased left ventricular mass and diastolic dysfunction are associated with endothelial dysfunction in normotensive offspring of subjects with essential hypertension. Blood Press. 2007;16(1):36-44.

14.

Makris TK , Stavroulakis GA , Krespi PG , et al. Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. Am J Hypertens . 2000;13(7):783-788.

15.

Sakata K. , Pawlak R. , Urano T. , Takada A. Effects of a long-term pharmacological interruption of the renin-angiotensin system on the fibrinolytic system in essential hypertension. Pathophysiol Haemost Thromb. 2002;32(2):67-75.

16.

Bronner LL , Kanter DS , Manson JE Primary prevention of stroke. N Engl J Med. 1995;333(21):1392-1400.

17.

Kizer JR , Dahlöf B. , Kjeldsen SE , et al. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension. 2005;45(1):46-52.

18.

Thögersen AM , Jansson JH , Boman K. , et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation. 1998;98(21):2241-2247.

19.

Robinson SD , Ludlam CA , Boon NA , Newby DE Endothelial fibrinolytic capacity predicts future adverse cardiovascular events in patients with coronary heart disease . Arterioscler Thromb Vasc Biol. 2007;27(7):1651-1656.

20.

Devereux RB , de Faire U. , Fyhrquist F. , et al. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy . Curr Med Res Opin. 2007;23(2):259-270.